Roche’s freshly approved PI3K inhibitor Itovebi can help extend the lives of certain patients with breast cancer when used in ...
Low-dose aspirin significantly reduced risk for colorectal cancer recurrence among patients with mutations in the PI3K ...
The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Kα inhibitor currently in a Phase 1/2 clinical trial STX ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback